Related Experiment Video
Updated: May 7, 2026
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Potential beneficial effect of treatment with PCSK9 inhibitors on vascular endothelial dysfunction: a systematic
Christina Antza1, Panagiota Anyfanti1, Charalampia Savva2
13rd Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Introduction:
PCSK9 inhibitors (PCSK9i) are at the center of research for their pleiotropic effects. The aim of this study is to systematically review the literature for their effect on vascular endothelial dysfunction.
Methods:
We systematically researched Embase, Ovid MEDLINE and CENTRAL for this purpose. Eligible studies were those assessing endothelial function by available noninvasive vascular methods. Meta-analysis was performed to compare differences on endothelial dysfunction between PCSK9i and placebo. Qualitative analysis was used for observational studies evaluating the outcome before and after PCSK9i.
Results:
We found 8 articles eligible, with the main outcome, among others, to be changes on flow-mediated dilation (FMD). Observational studies report an increase on FMD after PCSK9i treatment. Only 5 studies (415 participants) were eligible for the meta-analysis. Compared to placebo, PCSK9i increased FMD but not statistically significant (MD:0.84, 95%CI:-0.07,1.74). Alirocumab was associated with no difference in two studies (MD:-0.20, 95%CI:-0.73,0.34), whereas evolocumab with a statistically significant increase in FMD in four studies (MD:1.31, 95%CI:0.22,2.4).
Conclusion:
This is the first effort to summarize evidence on the effect of PCSK9i on endothelial function. PCSK9i may improve FMD, suggesting additional therapeutic roles beyond the traditional ones. Further, high-quality, large population studies are needed to confirm these findings.
Protocol Registration:
The protocol utilized for this research is available in the Open Science Framework (OSF) database (https://osf.io/hz4d2/).
Related Concept Videos
01:26Atherosclerosis III: Management
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:27Peripheral Artery Disease III: Interprofessional Care
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Coronary Artery Disease I: Introduction